Vedolizumab for treating moderately to severely active ulcerative colitis

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment - guidance review (PDF 160 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination document (PDF 452 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers (PDF 2.95 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: appraisal consultation

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: appraisal consultation document (PDF 684 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: evaluation report and supporting information information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1 (PDF 5.64 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2 (PDF 5.23 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 3 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 3 (PDF 5.04 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment form (post referral) (PDF 119 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: NICE response to consultee and commentator comments on the draft scope and provisional matrix (post-referral) (PDF 275 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final matrix (post-referral) (PDF 105 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final scope (post-referral) (PDF 126 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: draft scope for consultation (pre-referral) - August 2013 (PDF 116 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: provisional matrix (pre-referral) - August 2013 (PDF 104 KB)